Related posts

Stocks rebound amid earningsTSX hits highs, Wall Street flatTSX closes March on a high
Investor Insights

This summary was created by AI, based on 13 opinions in the last 12 months.

Moderna (MRNA-Q) is a company that made the first Covid vaccine and experienced a surge in sales, but is now facing losses. It is working on a drug pipeline and a personalized cancer vaccine, but the success timeline is uncertain. The stock has experienced significant fluctuations in recent months, but some experts believe in the company's technology and future prospects.

Consensus
Mixed
Valuation
Fair Value
WATCH
Moderna

A staple, and that sector is starting to outperform the market. A value play. His target is around $200-ish, if it can break resistance around $140. If it fails, give it a few days, and then walk away if you have to.

Pharma & Healthcare
WAIT
Moderna

They have special technology; this morning they announced a collaboration with AI. Shares have been declining and there are sellers everywhere. You have to wait until they invent the special vaccines en masse they promised.

Pharma & Healthcare
BUY ON WEAKNESS
Moderna

Believes in the CEO and their technology. Buy below $100.

Pharma & Healthcare
DON'T BUY
Moderna

Down 44% in 2023. They made the first Covid vaccine and made a ton of sales, but they suffer losses now. It didn't pull off a cancer vaccine as some hoped for. But it's up 9% in the past week. Maybe there's hope.

Pharma & Healthcare
DON'T BUY
Moderna

Covid vaccine was its first commercial product, and it did well. That's trailing off. Investing in drug pipeline, and it's hard to determine when products might be approved and launched. Her preference is a more established company with a pipeline.

Pharma & Healthcare
RISKY
Moderna
JNJ question

A good mix of consumer goods and healthcare, but the PE is extended. Prefers to buy Pfizer for its growth and lower PE. He might even roll the dice with Moderna. Or buy the IBB, biotech ETF.

Pharma & Healthcare
premium

This is a Panic-proof Portfolio opinion which is available only for Premium members

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK
Moderna
(A Top Pick May 04/23, Down 19.5%)Stockchase Research Editor: Michael O'Reilly

Our PAST TOP PICK with MRNA has triggered its stop at $110.  To remain disciplined we recommend covering the position at this time.  

Pharma & Healthcare
COMMENT
Moderna

Down 26% in the last 23 months. It's suffering a post-Covid hangover and the company is better than this.

Pharma & Healthcare
premium

This is a Panic-proof Portfolio opinion which is available only for Premium members

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK
Moderna
(A Top Pick May 04/23, Down 9.3%)Stockchase Research Editor: Michael O'Reilly

Our PAST TOP PICK with MRNA is stagnating.  To be disciplined, we recommend trailing up the stop (from $100) to $110 at this time.  

Pharma & Healthcare
PARTIAL BUY
Moderna

Is down 22% in the last 3 months. But he would but it. They're out of fashion, sure, and it's considered a Covid name, but their science is very good. A personalized cancer vaccine is possible.

Pharma & Healthcare
BUY
Moderna

They have developed a vaccine template that will benefit them going forward. Do not sell, but add more.

Pharma & Healthcare
WATCH
Moderna

In past years, biotech was the safe trade, but this year risk is back, so these stocks have fallen out of favour. Also, there are so many drugs in trials now and big pharma needs new product. She's looking at Gilead and Moderna, because they have low PEs and alot of drugs in development. However, the overall sector is risky. 

Pharma & Healthcare
COMMENT
Moderna

They're holding an investor event on Monday. They delivered an early Covid vaccine, but shares have fallen since then. A smart CEO. They're working on a personalized cancer medication. 

Pharma & Healthcare
COMMENT
Moderna

The risk/return is elevated so be careful.

Pharma & Healthcare
premium

This is a Panic-proof Portfolio opinion which is available only for Premium members

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

TOP PICK
Moderna
Stockchase Research Editor: Michael O'Reilly

The stock price has been impacted by news of reduced sales of its COVID19 vaccine.  This is to be expected as governments draw down their previously purchased inventory and uptake slows with re-opening.  COVID is not going away anytime soon with booster shots expected in the fall.  Recently reported earnings beat expectation, showing a gain when analysts expected a loss.  The company is also working on a RSV vaccine.  It trades at 7x earnings and supports a ROE of 50%.  We recommend placing a stop loss at $100, looking to achieve $199 -- upside potential of 45%.  Yield 0% 

(Analysts’ price target is $198.77)
Pharma & Healthcare
Showing 1 to 15 of 53 entries

Moderna(MRNA-Q) Rating

Ranking : 4 out of 5

Bullish - Buy Signals / Votes : 6

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 2

Total Signals / Votes : 8

Stockchase rating for Moderna is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Moderna(MRNA-Q) Frequently Asked Questions

What is Moderna stock symbol?

Moderna is a American stock, trading under the symbol MRNA-Q on the NASDAQ (MRNA). It is usually referred to as NASDAQ:MRNA or MRNA-Q

Is Moderna a buy or a sell?

In the last year, 8 stock analysts published opinions about MRNA-Q. 6 analysts recommended to BUY the stock. 2 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Moderna.

Is Moderna a good investment or a top pick?

Moderna was recommended as a Top Pick by on . Read the latest stock experts ratings for Moderna.

Why is Moderna stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Moderna worth watching?

8 stock analysts on Stockchase covered Moderna In the last year. It is a trending stock that is worth watching.

What is Moderna stock price?

On 2024-05-24, Moderna (MRNA-Q) stock closed at a price of $166.61.